2023 ISAKOS Biennial Congress ePoster
Injectable Orthobiologics in Professional Football (Soccer) Players: A Systematic Review
Theodorakys Marín Fermín, MD, Caracas, Distrito Capital VENEZUELA
Emmanouil Papakostas, MD, FEBSM, Doha QATAR
Luca Macchiarola, MD, Foggia ITALY
Frantzeska Zampeli, MD, PhD, Athens GREECE
Georgios Kalifis, MD, Larisa, Europe GREECE
Laura de Girolamo, PhD, Milan ITALY
Bashir Zikria, MD MSc., Bethesda, MD UNITED STATES
Miguel Angel Khoury, MD, Buenos Aires ARGENTINA
Pieter D'Hooghe, MD PhD MBA MSc, London UNITED KINGDOM
Aspetar Orthopaedic and Sports Medicine Hospital, Doha, QATAR
FDA Status Not Applicable
Summary
There is scarce evidence on orthobiologics implementation in professional football players other than PRP injections to treat muscle, ligament cartilage, bone, tendon, fascial, and capsular injuries. However, evidence lacks methodological quality and adherence to the minimum information for studies evaluating biologics in orthopaedics to support its implementation.
ePosters will be available shortly before Congress
Abstract
Introduction
The use of orthobiologics in the treatment of sports injuries has increased because of athletes’ desire to heal faster and early return to sports. These therapies comprise platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and mesenchymal stem cells (MSCs) injections which promote the native musculoskeletal system healing and regeneration potential.
Objectives: To evaluate the clinical outcomes of PRP, BMAC, and MSCs injections in treating sport-related injuries for professional football (PF) players.
Methods
Following the PRISMA guidelines, PubMed, Embase, Scopus, and The Cochrane Central Register of Controlled Trials (CENTRAL) databases were accessed in January 2022. Clinical studies evaluating the outcomes of PRP, BMAC, and MSCs injections in sports-related injuries among PF players were considered eligible. The methodological quality was assessed using the modified Coleman Methodology Score (mCMS), and a short version of the Minimum Information for studies evaluating Biologics in Orthopaedics (MIBO) was recorded for every PRP study.
Results
Eleven studies met the eligibility criteria. All implemented PRP, most of them in treating muscle and ligament injuries. Only one study implemented BMAC, and no study implementing MSCs injections in PF players was found. The average mCMS value demonstrated a poor level of methodological quality. Studies reported only 26.13% of the relevant data of the short-MIBO.
Conclusions
There is scarce evidence on orthobiologics implementation in PF players other than PRP injections to treat muscle, ligament cartilage, bone, tendon, fascial, and capsular injuries. However, evidence lacks methodological quality and adherence to MIBO to support its implementation.